Skip to contentC
CRISPR Therapeutics AG
C
CRSPCRISPR Therapeutics AG Q3 2018 · 10-Q
Revenue$563.00K$563.00K−76.4% vs Q3 2017 Net Income-$50.71M-$50.71MN/M vs Q3 2017 EPS Diluted-$1.07-$1.07N/M vs Q3 2017 Operating Income-$49,432,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
CRISPR Therapeutics AG · CIK 1674416 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$20,659,000N/M Margins · derivedOperating margin-8780.1%−7792.7 pt vs Q3 2017
Net margin-9007.3%−7972.2 pt vs Q3 2017
ended Sep 30, 2018 · filed Nov 7, 2018 · 38 d after period end